Beranda524804 • BOM
add
Aurobindo Pharma Ltd
Tutup sebelumnya
₹1.223,95
Rentang hari
₹1.221,00 - ₹1.243,00
Rentang tahun
₹959,05 - ₹1.592,55
Kapitalisasi pasar
729,53Â M INR
Volume Rata-Rata
13,22Â rb
Rasio P/E
20,19
Hasil dividen
-
Bursa utama
NSE
Dalam berita
Keuangan
Laporan Pendapatan
Pendapatan
Laba bersih
| (INR) | Sep 2024info | Perubahan Y/Y |
|---|---|---|
Pendapatan | 77,96Â M | 7,99% |
Biaya operasional | 34,02Â M | 13,51% |
Laba bersih | 8,17Â M | 7,95% |
Margin laba bersih | 10,48 | -0,10% |
Penghasilan per saham | 14,00 | 9,12% |
EBITDA | 15,77Â M | 16,15% |
Tarif pajak efektif | 32,34% | — |
Neraca
Total aset
Total liabilitas
| (INR) | Sep 2024info | Perubahan Y/Y |
|---|---|---|
Investasi tunai jangka pdk | 68,68Â M | -3,93% |
Total aset | 480,94Â M | 9,50% |
Total liabilitas | 172,09Â M | 9,41% |
Total ekuitas | 308,85 M | — |
Saham yang beredar | 583,84 jt | — |
Harga terhadap nilai buku | 2,31 | — |
Tingkat pengembalian aset | — | — |
Tingkat pengembalian modal | 7,81% | — |
Arus Kas
Perubahan kas bersih
| (INR) | Sep 2024info | Perubahan Y/Y |
|---|---|---|
Laba bersih | 8,17Â M | 7,95% |
Kas dari operasi | — | — |
Kas dari investasi | — | — |
Kas dari pembiayaan | — | — |
Perubahan kas bersih | — | — |
Arus kas bebas | — | — |
Tentang
Aurobindo Pharma Limited is an Indian multinational pharmaceutical manufacturing company headquartered in HITEC City, Hyderabad. The company manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's area of activity includes six major therapeutic and product areas: antibiotics, anti-retrovirals, cardiovascular products, central nervous system products, gastroenterologicals, and anti-allergics. The company markets these products in over 125 countries. Its marketing partners include AstraZeneca and Pfizer. Wikipedia
Didirikan
1986
Kantor pusat
Situs
Karyawan
26.015
